Quinta-Analytica s.r.o.

The Clinical Unit advances therapies for serious bacterial and fungal diseases by evaluating how new formulations are absorbed and tolerated in healthy participants.

• Comparative bioavailability of oral antibiotics
• Pharmacokinetic profiling of antifungal suspensions
• Safety assessment in bioequivalence trials of antimicrobial agents
• Food‑effect studies on colistimethate sodium
• Drug‑drug interaction evaluation for combination antimicrobial therapy

Quinta‑Analytica conducts a substantial share of its 35 trials in this therapeutic area, supported by a dedicated team of seven investigators.

Research focuses on improving drug delivery and safety for conditions such as hypertension and thrombosis, using healthy‑subject studies to compare new products with established standards.

• Comparative bioavailability of statin combinations
• Pharmacokinetic assessment of antiplatelet agents
• Evaluation of oral anticoagulant formulations
• Food‑effect analysis for antihypertensive tablets
• Safety monitoring in crossover bioequivalence studies

The site’s cardiovascular portfolio reflects its commitment to rigorous early‑phase testing, contributing to better therapeutic options for patients.

Studies aim to optimize dosing and safety of treatments for urinary tract infections and reproductive health issues, primarily through pharmacokinetic comparisons in post‑menopausal volunteers.

• Bioequivalence of oral suspension for uncomplicated urinary infections
• Pharmacokinetic profiling of letrozole in post‑menopausal women
• Safety evaluation of new urogenital drug formulations
• Food‑interaction studies for antibiotics used in pregnancy
• Comparative absorption of hormonal agents

Quinta‑Analytica’s expertise in this niche supports the development of safer, more effective therapies for women’s health.

The unit investigates drug behavior for conditions affecting blood and lymphatic systems, emphasizing precise measurement of exposure and tolerability.

• Pharmacokinetic study of oral iron formulations
• Bioavailability comparison of anticoagulant tablets
• Safety assessment of novel lymphatic agents in healthy subjects
• Food‑effect evaluation for agents influencing blood clotting
• Crossover trials measuring systemic exposure of hematologic drugs

The focus on accurate exposure data helps streamline later‑stage trials for blood‑related therapies.

Research targets improved treatment of bone and joint disorders by comparing the absorption of analgesics, anti‑inflammatories, and bone‑health medications.

• Bioequivalence of ibuprofen formulations
• Pharmacokinetic profiling of alendronate tablets and effervescent versions
• Safety and absorption study of rotigotine transdermal patches
• Food‑effect assessment for naproxen modified‑release tablets
• Comparative bioavailability of combined antihypertensive‑osteoporosis capsules

By conducting these studies, Quinta‑Analytica contributes to faster access to effective musculoskeletal therapies.

Early‑phase trials evaluate how anticancer agents are absorbed and tolerated, supporting dose selection for later oncologic studies.

• Pharmacokinetic assessment of oral oncology drugs in fasted volunteers
• Bioavailability comparison of novel chemotherapeutic suspensions
• Safety monitoring of targeted therapy tablets
• Food‑interaction studies for oral cancer agents
• Crossover design to measure systemic exposure of investigational anticancer compounds

The site’s oncology focus aligns with its broader mission to accelerate innovative cancer treatment development.

Investigations center on central nervous system drugs, assessing how formulations cross the blood‑brain barrier and their safety profiles.

• Bioequivalence of transdermal patches for Parkinson’s disease
• Pharmacokinetic study of antiepileptic tablets
• Safety evaluation of novel antidepressant formulations
• Food‑effect analysis for central nervous system agents
• Crossover trials measuring brain‑penetrant drug exposure

Quinta‑Analytica’s work aids in refining dosing strategies for neurological conditions.

The unit examines therapies for metabolic disorders, including diabetes and obesity, by comparing how different formulations are absorbed under various conditions.

• Bioavailability study of dapagliflozin tablets
• Pharmacokinetic comparison of combination antidiabetic capsules
• Food‑effect assessment for glucose‑lowering agents
• Safety monitoring of weight‑management drug formulations
• Crossover evaluation of insulin‑sensitizing compounds

These efforts support the development of more convenient and effective metabolic disease treatments.

Studies aim to improve topical and oral treatments for dermatologic conditions by measuring systemic exposure and tolerability.

• Bioequivalence of oral anti‑inflammatory agents for skin disorders
• Pharmacokinetic profiling of oral corticosteroid suspensions
• Food‑interaction study for oral acne medications
• Safety assessment of new connective‑tissue disease drugs
• Crossover trials evaluating systemic absorption of dermatologic therapies

Quinta‑Analytica contributes valuable early data that inform dosing recommendations for skin‑related medicines.

The clinical unit conducts bioavailability and safety studies for antiviral agents, supporting the development of treatments for acute and chronic viral infections.

• Comparative bioavailability of valacyclovir oral suspension
• Pharmacokinetic assessment of antiviral tablets under fasting and fed conditions
• Food‑effect evaluation for oral antiviral formulations
• Safety monitoring in crossover studies of antiviral drugs
• Crossover design to compare systemic exposure of different antiviral brands

These investigations help ensure that new antiviral products achieve reliable exposure and safety profiles.

Research explores how drugs influence muscle and nerve function, focusing on pharmacokinetic behavior and safety in healthy volunteers.

• Bioavailability of analgesic combinations targeting muscular pain
• Pharmacokinetic profiling of neuromuscular agents
• Safety assessment of drugs affecting nerve conduction
• Food‑effect studies on muscle‑relaxant formulations
• Crossover trials measuring systemic exposure of neural physiologic modulators

Quinta‑Analytica’s investigations provide foundational data for future therapies aimed at musculoskeletal and neural health.

Early‑phase studies assess the absorption and tolerability of psychiatric medications, supporting the development of safer, more effective treatments.

• Bioequivalence of antipsychotic tablets
• Pharmacokinetic comparison of mood‑stabilizing formulations
• Safety monitoring of novel antidepressant agents
• Food‑effect evaluation for psychiatric drug suspensions
• Crossover design to assess systemic exposure of anxiolytic compounds

The site’s work in this area contributes to improved therapeutic options for patients with mental health conditions.

For studies where the therapeutic focus cannot be precisely categorized, the Clinical Unit still conducts rigorous bioavailability and safety assessments to support diverse drug development programs.

• General bioequivalence studies in healthy volunteers
• Pharmacokinetic profiling of investigational compounds
• Safety and tolerability evaluation across multiple dosage forms
• Food‑effect investigations for a range of oral products
• Crossover designs enabling within‑subject comparison of drug exposure

These flexible studies enable Quinta‑Analytica to contribute valuable data to a wide spectrum of therapeutic areas.